Quadrivalent human papillomavirus vaccine: two vaccine doses was also associated with a considerable reduction in condyloma risk
Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility.
Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus ( HPV ) vaccines.
Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
A study has examined the association between quadrivalent HPV vaccination and first occurrence of condyloma in relation to vaccine dose in a population-based setting.
An open cohort of all females aged 10 to 24 years living in Sweden ( n = 1 045 165 ) was followed up between 2006 and 2010 for HPV vaccination and first occurrence of condyloma using the Swedish nationwide population-based health data registers.
Incidence rate ratios ( IRRs ) and incidence rate differences ( IRDs ) of condyloma were estimated using Poisson regression with vaccine dose as a time-dependent exposure, adjusting for attained age and parental education, and stratified on age at first vaccination.
A total of 20 383 incident cases of condyloma were identified during follow-up, including 322 cases after receipt of at least 1 dose of the vaccine.
For individuals aged 10 to 16 years at first vaccination, receipt of 3 doses was associated with an IRR of 0.18 for condyloma, whereas receipt of 2 doses was associated with an IRR of 0.29.
One dose was associated with an IRR of 0.31, which corresponds to an IRD of 384 cases per 100 000 person-years, compared with no vaccination.
The corresponding IRDs for 2 doses were 400 cases and for 3 doses, 459 cases.
The number of prevented cases between 3 and 2 doses was 59 per 100 000 person-years.
In conclusion, although maximum reduction in condyloma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associated with a considerable reduction in condyloma risk. ( Xagena )
Herweijer E et al, JAMA 2014;311:597-603
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...
First-line therapy with Dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma
Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the...
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say...
Axalimogene filolisbac, a listeria-based HPV immunotherapy, in second and third-line metastatic cervical cancer
Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ),...
A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a...
Impact of human papillomavirus on distant metastatic failure patterns in squamous cell cancer of the oropharynx in patients treated with chemoradiation
HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic...
Women older than 25 years: efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine, 4-year follow-up
Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at...
A small number of cases of complex regional pain syndrome following vaccination have been reported to the TGA ( Therapeutic...